Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- After Abysmal Year, Kinetic Concepts Granted FDA Clearance for New LifeCell Product
- Douglas Cress submits: Kinetic Concepts KCI has received FDA 510[k] clearance for its LifeCell Tissue Matrix. The matrix is used to treat chronic, trauma, surgical and other acute wounds. The product utilizes the company’s Strattice technology, a sterile reconstructive tissue matrix that supports tissue regeneration. Strattice is derived from pig...
- External links 2008-10-16
- Clarient: New Breast-Cancer Test
- Douglas Cress submits: For women who survive breast cancer, the triumph of beating the odds is often tempered by a fear of the cancer returning. A study published last year in the Journal of the National Cancer Institute looked at 3,000 breast cancer patients, and found that the group averaged...
- External links 2009-05-05
- Cynosure Revenues Fall: Disappointing But Expected
- Douglas Cress submits: Cynosure CYNO released preliminary fourth quarter results last week: the company expects revenues of $25 million to $26 million; in the same quarter last year, Cynosure reported revenues of $36.6 million. The company had been profitable for eight consecutive quarters, but will report a $2.2 - $2.7...
- External links 2009-01-18
- AngioDynamics' Less Than Stellar Quarter
- Douglas Cress submits: It’s been a roller coaster of a year for AngioDynamics ANGO. In the past, I’ve professed my high opinion of the company. I still like ANGO and I think it’s fairly valued, but a less than stellar quarter should give growth-obsessed investors pause. The company expects revenues...
- External links 2009-01-09
- Endologix Is Smooth Sailing in Q4
- Douglas Cress submits: Endologix ELGX, developer of Powerlink, a treatment for abdominal aortic aneurysms [AAA], posted another strong quarter. I am an unabashed fan of the company which, in November, rejected a $98 million ($2.25/ share) buyout offer from New York-based hedge fund, Elliott Associates. Commenting on that decision, John...
- External links 2009-01-06
- Electro-Optical Sciences' Shares Up on Trial Results Announcement
- Douglas Cress submits: Irvington-NY based Electro-Optical Sciences MELA, developer of The MelaFind System, a handheld imaging device that detects melanomas at an early stage, announced last week that its pivotal trial sites have closed: all follow-up data has been received and is now undergoing third-party statistical validation. The company will...
- External links 2009-01-05
- Novadel Longs May Finally Get a Good Night's Sleep
- Douglas Cress submits: The FDA has approved NovaDel’s NVD Zolpimist, an oral spray for the short-term treatment of insomnia. Zolpimist contains zolpidem tartrate, the same active ingredient found in Ambien. Until recently, the U.S. patent for zolpidem was held by the French pharmaceutical giant Sanofi-Aventis SNY. In April 2007, the...
- External links 2008-12-22
- Synergetics USA Posts Strong Q1 Results
- Douglas Cress submits: Synergetics USA SURG reported first quarter revenues of $12.2 million, an increase of 17% over the year ago period. More compelling was the increase in net income: $661,000 in the most recent quarter compared to $397,000 in Q1 2008, a 66% improvement. In the past year, the...
- External links 2008-12-09
- AngioDynamics: Good Time to Buy
- Douglas Cress submits: Changes are afoot at Queensbury NY-based AngionDynamics ANGO. The company said on Wednesday that it would begin the search for a new CEO to replace company co-founder Eamonn Hobbs. Hobbs will continue on as Vice Chairman of the Board of Directors where he will focus on the...
- External links 2008-12-05
- Endologix Rejects Elliott Associates' Buyout Bid As Too Cheap
- Douglas Cress submits: Regular Sentinel readers know I’m a fan of Endologix ELGX. The developer of a minimally invasive treatment for abdominal aortic aneurysms has had a slate of positive news of late. In addition to two new FDA clearances, in its third quarter, the company significantly improved its liquidity...
- External links 2008-11-14
- Is NxStage Medical Losing It?
- Douglas Cress submits: NxStage Medical NXTM may be losing steam. The maker of dialysis products reported third quarter revenues of $30.5 million, a slight decrease from the $31.6 million reported last quarter. Call Transcript While revenues in the company’s home dialysis business grew slightly ($12.4 million in Q3 2008, compared...
- External links 2008-11-04
- Clarient: With Quarterly Revenues Up 59%, Take a Look
- Douglas Cress submits: Third quarter revenues at Clarient CLRT increased 59% to $19.0 million from the $11.9 million reported in Q3 2007. This marks the company’s 17th consecutive quarter of sequential revenue growth. Higher testing volume, a favorable service mix and higher Medicare reimbursement rates drove revenues. Testing volume for...
- External links 2008-11-02
- Cynosure: Little Investor Interest Though Profitable, Growing & Flush With Cash
- Douglas Cress submits: Quarterly revenues at Cynosure CYNO, a developer of laser-based aesthetic systems, grew 21% year-over-year, from $31.5 million in Q3 2007 to $38.2 million in the most recent quarter. Second quarter revenues were $39.2 million. Net income for the third quarter of 2008 was $3.2 million compared with...
- External links 2008-10-29
- But Why? Despite Positives, Endologix Shares Down
- Douglas Cress submits: Endologix ELGX, developer of a treatment for abdominal aortic aneurysms [AAA], saw revenues increase 42% in its third quarter. The company reported $9.4 million in sales and expects “at least” $10 million in fourth quarter revenue. If all goes to plan, Endologix is on track for full-year...
- External links 2008-10-24
- Endologix: Business as Usual as It Considers $98M Buyout
- Douglas Cress submits: More good news from Endologix ELGX, the Irvine, CA-based company mulling over a $98 million buyout bid from hedge fund Elliott Associates. This week, the company’s IntuiTrak Delivery System was approved by the FDA. The System will be used to deliver and deploy the company’s stent graft,...
- External links 2008-10-23
- Onyx / Proteolix: Checking the Synergy of the Acquisition
- Douglas Cress submits: Onyx Pharmaceuticals ONXX has agreed to purchase private biotechnology company Proteolix for $276 million in cash, Bloomberg reports. The acquisition will provide Onyx with a late-stage, next-generation therapy to treat multiple myeloma, a form of blood cancer that affects over 180,000 people worldwide. Shares in Onyx rose...
- External links 2009-10-13
Additional Resources
- NeuroMetrix: Revenues Decline, Prospects Look Bleak
- Douglas Cress submits: NeuroMetrix NURO reported quarterly revenues of $8.5 million on Tuesday, down approximately 26% from the same period in 2007. The company generated a scant $510,000 (or 6% or revenues) from the sale of devices, including NC-stat System and the newer Advance. That could spell trouble for future...
- External links 2008-08-07
- Clarient: Clearly a Winner
- Douglas Cress submits: Not wanting to break a winning streak, Clarient CLRT delivered its 16th consecutive quarter of quarterly revenue growth. The company posted revenues of $16.9 million in its most recent quarter, a 71% increase over the same period last year. Based on performance in the first half of...
- External links 2008-08-11
- Retractable Technologies: Moving Towards Profitability
- Douglas Cress submits: In May, I reported stagnation at Retractable TechnologiesRVP, a Texas-based safety needle manufacturer. Pointing to a robust balance sheet, I recommended the company makes some moves. I’d like to think my call to action was responsible for this quarter’s promising results: by Douglas Cress
- External links 2008-08-13
- Thermage: Robust Q2 Results in Ailing Aesthetics Market
- Douglas Cress submits: Despite the slowdown seen in the aesthetics market, second quarter revenue at Thermage THRM totaled $17.9 million, a 2% increase over Q2 2007. International revenue increased 10 percent while domestic revenues declined four percent. The company offset weaker sales of its ThermCool system by selling more treatment...
- External links 2008-08-13
- << Previous
- page 1 of 1
- Next >>
